ClinicalTrials.gg
CompletedNCT00112112Updated Aug 14, 2017Results posted

Safety Study to Evaluate FluMist in Immunocompromised Children

A Phase 1 interventional study of FluMist and Placebo in Cancer, sponsored by MedImmune LLC. Completed at 5 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-08-14.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Study summary

The main purpose of this study is to get information about the safety of a flu vaccine spray, called FluMist, in children with cancer. The study is also being done to find out how much and how long the vaccine spray can be found in the nose.

Read the detailed description

This study is a randomized, double-blind Phase 1 study of FluMist vs. placebo in mild to moderately immunocompromised children 5 to 17 years of age with cancer. The primary objective of this study is to describe the safety of FluMist compared with placebo in mild to moderately immunocompromised children with cancer. The secondary objectives of this study are to describe the immune responses following vaccination with FluMist and to determine the incidence and duration of viral replication following vaccination with FluMist.

The standard 0.5 mL dose of vaccine or placebo was administered intranasally. Patients were evaluated at four visits scheduled between days 3-5, days 7-10, days 14-28, and days 35-42 for viral shedding via nasal swabs. Safety outcomes were collected at study clinic visits or by telephone contact through 42 days post dose. Serious adverse events and significant new medical conditions were collected through 180 days after receipt of investigational product.

Immune responses were measured by detection of influenza-specific antibodies as measured by the standard hemagglutination inhibition (HAI) assay. Influenza-specific serum antibody isotype levels were determined and nasal swab specimens were analyzed for the expression of influenza-specific immunoglobulin A (IgA). Serum was analyzed for its ability to neutralize viral particles from infecting Madin-Darby canine kidney cells (microneutralization). Baseline immunosuppression as measured by expression of T- and B-lymphocyte subsets was compared to immunosuppression at time points after vaccination. The duration of viral replication and the titers of live-attenuated influenza virus shed was evaluated from nasal swab specimens collected at scheduled time points after administration of FluMist.

02

Conditions studied

  • Cancer

Keywords

  • cancer, pediatric, influenza, vaccine
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 20 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted before MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5 through 17 years of age (not yet reached their 18th birthday) at the time of entry into the study;
  • Patient's parent or legal guardian available by telephone during the course of the study;
  • Written (assent if applicable) and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the patient's parent or legal guardian;
  • Ability of the patient or patient's parent/guardian to comply with the requirements of the protocol;
  • Currently receiving chemotherapy and/or radiation therapy for the treatment of cancer or have received chemotherapy in the past 12 weeks;
  • If the subject's underlying cancer is a solid tumor, current status must be stable disease, partial response, or complete response to therapy; if the subject's underlying disease is a hematologic , current status must be in remission;
  • Estimated of >1 year; and
  • Currently has no worse than mild to moderate (meets none of the exclusion criteria).

Exclusion criteria

Exclusion Criteria:

  • History of to any component of FluMist, including egg or egg products, or monosodium glutamate;
  • History of hypersensitivity to gentamicin;
  • Close contact with a severely patient (e.g., a hematopoietic stem cell transplant patient, during those periods in which the immunocompromised patient requires care in a protective environment);
  • History of Guillain-Barré syndrome;
  • History of asthma;
  • Use of aspirin or salicylate-containing products in the 30 days prior to study vaccination or expected receipt within the study duration;
  • Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to enrollment or expected receipt (unless medically indicated) during this study;
  • Currently receiving inhaled therapy;
  • Receipt of immunoglobulin within the past 90 days;
  • Receipt of stem cell transplant;
  • Acute febrile [>100.0°F (37.8°C) oral] illness or acute respiratory illness, e.g., cough or sore throat, within three days prior to enrollment;
  • Administration of any within 30 days prior to enrollment or if receipt of another live vaccine is expected within 30 days after the vaccination in this study;
  • Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks after the vaccination in this study;
  • Receipt of an product studied under an investigational new drug (IND) within 10 days prior to study entry or expected receipt of such an investigational product within 10 days after study vaccination (Note: an investigational product not studied under an IND is allowed at the investigator's discretion);
  • Pregnancy or, in biologically capable females (e.g., menses within the last year), not willing to agree to acceptable for three months after study vaccination (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
  • Female who is breastfeeding or lactating;
  • Any condition or receipt of other medication that, in the opinion of the investigator, might interfere with the evaluation of the vaccine or interpretation of study results;
  • At the study screening visit (within 16 days before study vaccination) a CD4+ T cell percentage of \<15%;
  • At study entry, an less than or equal to 500 cells/mm3;
  • Receipt of high-dose systemic corticosteroids (≥ 2 mg/kg total of prednisone or equivalent given daily or on alternating days) for ≥ 14 consecutive days within 30 days prior to or following study vaccination
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    FluMist

    The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.

    Biological: FluMist

  • Placebo comparator
    Placebo

    Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

    Biological: Placebo

Interventions

  • BiologicalFluMist

    The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like. brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.

  • BiologicalPlacebo

    Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had Reactogenicity Events (REs)

    Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration. The REs for this study included fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.

    Time frame: 0-42 days after study vaccination

  2. Number of Participants Who Had Serious Adverse Events (SAEs)

    An SAE is any AE that results in any of the following outcomes: •Death • Life-threatening • Inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity • Congenital anomaly/birth defect (in the offspring of a study participant) • An important medical event that may may jeopardize the study participant and may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: 0-180 days after study vaccination

  3. Number of Participants Who Had Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigations study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: 0-42 days after study vaccination

  4. Number of Significant New Medical Conditions (SNMCs)

    A significant new medical condition is defined as a new diagnosis of a chronic medical condition that does not meet the criteria of a SAE.

    Time frame: 43-180 days after study vaccination

Secondary outcomes

  1. Number of Participants Shedding Vaccine-like Virus

    Number of participants with nasal swab samples that contained vaccine-like virus are reported.

    Time frame: 3-5 days after study vaccination

  2. Number of Participants Shedding Vaccine-like Virus

    Number of participants with nasal swab samples that contained vaccine-like virus are reported.

    Time frame: 7-10 days after study vaccination

  3. Number of Participants Shedding Vaccine-like Virus

    Number of participants with nasal swab samples that contained vaccine-like virus are reported.

    Time frame: 14-28 days after study vaccination

  4. Number of Participants Shedding Vaccine-like Virus

    Number of participants with nasal swab samples that contained vaccine-like virus are reported. Sample was collected at this time point only if health assessment indicated presence of a respiratory illness, including otitis media.

    Time frame: 35-42 days after study vaccination

  5. Number of Participants Shedding Vaccine-like Virus

    Number of participants with nasal swab samples that contained vaccine-like virus are reported.

    Time frame: Unscheduled visits occurring during 0-42 days after study vaccination

  6. T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19

    Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: pre-dosing (Day 0)

  7. T- and B-lymphocyte Subsets by Flow Cytometry - CD3

    Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: pre-dosing (Day 0)

  8. T- and B-lymphocyte Subsets by Flow Cytometry - CD4

    Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: pre-dosing (Day 0)

  9. T- and B-lymphocyte Subsets by Flow Cytometry - CD8

    Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: pre-dosing (Day 0)

  10. T- and B-lymphocyte Subsets by Flow Cytometry - CD19

    Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: 7-10 days after study vaccination

  11. T- and B-lymphocyte Subsets by Flow Cytometry - CD3

    Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: 7-10 days after study vaccination

  12. T- and B-lymphocyte Subsets by Flow Cytometry - CD4

    Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: 7-10 days after study vaccination

  13. T- and B-lymphocyte Subsets by Flow Cytometry - CD8

    Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.

    Time frame: 7-10 days after study vaccination

  14. Interferon (INF)-Gamma

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: pre-dosing (Day 0)

  15. INF-Gamma

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: 7-10 days after study vaccination

  16. INF-Gamma

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: 35-42 days after study vaccination

  17. Interleukin (IL)-4

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: pre-dosing (Day 0)

  18. IL-4

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: 7-10 days after study vaccination

  19. IL-4

    Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

    Time frame: 35-42 days after study vaccination

  20. Human Leukocyte Antigen (HLA) Matched Tetramers CD8+

    The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

    Time frame: pre-dosing (Day 0)

  21. HLA Matched Tetramers CD8+

    The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

    Time frame: 7-10 days after study vaccination

  22. HLA Matched Tetramers CD8+

    The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

    Time frame: 35-42 days after study vaccination

  23. Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  24. Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  25. Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  26. Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  27. Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  28. Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42

    Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

    Time frame: Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination

  29. Influenza A/H1N1 Immunoglobulin A (IgA)

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  30. Influenza A/H1N1 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 3-5 days after study vaccination

  31. Influenza A/H1N1 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 7-10 days after study vaccination

  32. Influenza A/H1N1 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 14-28 days after study vaccination

  33. Influenza A/H1N1 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  34. Influenza A/H3N2 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  35. Influenza A/H3N2 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 3-5 days after study vaccination

  36. Influenza A/H3N2 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 7-10 days after study vaccination

  37. Influenza A/H3N2 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 14-28 days after study vaccination

  38. Influenza A/H3N2 IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  39. Influenza B IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  40. Influenza B IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 3-5 days after study vaccination

  41. Influenza B IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 7-10 days after study vaccination

  42. Influenza B IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 14-28 days after study vaccination

  43. Influenza B IgA

    Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  44. T- and B-lymphocyte Subsets by Flow Cytometry - CD56

    Mean and standard deviation results of CD56 lymphocyte subsets is reported.

    Time frame: pre-dosing (Day 0)

  45. T- and B-lymphocyte Subsets by Flow Cytometry - CD56

    Mean and standard deviation results of CD56 lymphocyte subsets is reported.

    Time frame: 7-10 days after study vaccination

  46. T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells

    Mean and standard deviation results of white blood cells subsets is reported.

    Time frame: pre-dosing (Day 0)

  47. T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells

    Mean and standard deviation results of white blood cells subsets is reported.

    Time frame: 7-10 days after study vaccination

  48. T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes

    Mean and standard deviation results of lymphocytes subsets is reported.

    Time frame: pre-dosing (Day 0)

  49. T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes

    Mean and standard deviation results of lymphocytes subsets is reported.

    Time frame: 7-10 days after study vaccination

  50. T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes

    Mean and standard deviation results of absolute lymphocytes subsets is reported.

    Time frame: pre-dosing (Day 0)

  51. T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes

    Mean and standard deviation results of absolute lymphocytes subsets is reported.

    Time frame: 7-10 days after study vaccination

  52. T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils

    Mean and standard deviation results of absolute neutrophils subsets is reported.

    Time frame: pre-dosing (Day 0)

  53. Influenza A/H1N1 Immunoglobulin G (IgG)

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  54. Influenza A/H1N1 IgG

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  55. Influenza A/H3N2 IgG

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  56. Influenza A/H3N2 IgG

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  57. Influenza B IgG

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  58. Influenza B IgG

    Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  59. Influenza A/H1N1 Immunoglobulin M (IgM)

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  60. Influenza A/H1N1 IgM

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  61. Influenza A/H3N2 IgM

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  62. Influenza A/H3N2 IgM

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

  63. Influenza B IgM

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: pre-dosing (Day 0)

  64. Influenza B IgM

    Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

    Time frame: 35-42 days after study vaccination

07

Results

Posted Sep 3, 2012

Participant flow

A total of 20 participants, 10 in the FluMist group and 10 in the placebo group, were enrolled in the study between 08Aug2005 and 31Mar2008 at 4 sites in the USA.

Participant flow — Overall Study
MilestonePlaceboFluMist
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryNumber of Participants Who Had Reactogenicity Events (REs)

Reactogenicity events (REs) are predefined solicited adverse events (AEs) that can potentially occur after vaccine administration. The REs for this study included fever, runny nose/nasal congestion, sore throat, cough, vomiting, headache, muscle aches, chills, tiredness, and irritability.

Time frame:
0-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Had Reactogenicity Events (REs)
participantsFluMistPlacebo
Number of Participants Who Had Reactogenicity Events (REs)89
PrimaryNumber of Participants Who Had Serious Adverse Events (SAEs)

An SAE is any AE that results in any of the following outcomes: •Death • Life-threatening • Inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity • Congenital anomaly/birth defect (in the offspring of a study participant) • An important medical event that may may jeopardize the study participant and may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
0-180 days after study vaccination
Reported as:
Number · Participants
Number of Participants Who Had Serious Adverse Events (SAEs)
ParticipantsFluMistPlacebo
Number of Participants Who Had Serious Adverse Events (SAEs)13
PrimaryNumber of Participants Who Had Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient or clinical investigations study participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
0-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Had Adverse Events (AEs)
participantsFluMistPlacebo
Number of Participants Who Had Adverse Events (AEs)610
PrimaryNumber of Significant New Medical Conditions (SNMCs)

A significant new medical condition is defined as a new diagnosis of a chronic medical condition that does not meet the criteria of a SAE.

Time frame:
43-180 days after study vaccination
Reported as:
Number · events
Number of Significant New Medical Conditions (SNMCs)
eventsFluMistPlacebo
Number of Significant New Medical Conditions (SNMCs)00
SecondaryNumber of Participants Shedding Vaccine-like Virus

Number of participants with nasal swab samples that contained vaccine-like virus are reported.

Time frame:
3-5 days after study vaccination
Reported as:
Number · participants
Number of Participants Shedding Vaccine-like Virus
participantsFluMistPlacebo
Number of Participants Shedding Vaccine-like Virus30
SecondaryNumber of Participants Shedding Vaccine-like Virus

Number of participants with nasal swab samples that contained vaccine-like virus are reported.

Time frame:
7-10 days after study vaccination
Reported as:
Number · participants
Number of Participants Shedding Vaccine-like Virus
participantsFluMistPlacebo
Number of Participants Shedding Vaccine-like Virus20
SecondaryNumber of Participants Shedding Vaccine-like Virus

Number of participants with nasal swab samples that contained vaccine-like virus are reported.

Time frame:
14-28 days after study vaccination
Reported as:
Number · participants
Number of Participants Shedding Vaccine-like Virus
participantsFluMistPlacebo
Number of Participants Shedding Vaccine-like Virus00
SecondaryNumber of Participants Shedding Vaccine-like Virus

Number of participants with nasal swab samples that contained vaccine-like virus are reported. Sample was collected at this time point only if health assessment indicated presence of a respiratory illness, including otitis media.

Time frame:
35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Shedding Vaccine-like Virus
participantsFluMistPlacebo
Number of Participants Shedding Vaccine-like Virus00
SecondaryNumber of Participants Shedding Vaccine-like Virus

Number of participants with nasal swab samples that contained vaccine-like virus are reported.

Time frame:
Unscheduled visits occurring during 0-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Shedding Vaccine-like Virus
participantsFluMistPlacebo
Number of Participants Shedding Vaccine-like Virus—0
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19

Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 19
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Cluster of Differentiation (CD) 198.6 ± 7.44.8 ± 8.3
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD3

Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD383.6 ± 8.989.1 ± 10.3
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD4

Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD447.3 ± 9.846.7 ± 7.5
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD8

Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD831.4 ± 8.138.8 ± 7.8
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD19

Mean and standard deviation results of CD19 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD19
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD1910.2 ± 10.85.1 ± 8.6
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD3

Mean and standard deviation results of CD3 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD3
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD382.0 ± 9.989.9 ± 11.6
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD4

Mean and standard deviation results of CD4 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD4
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD448.2 ± 11.846.5 ± 11.4
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD8

Mean and standard deviation results of CD8 lymphocyte subsets as a percentage of total lymphocytes.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD8
percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD827.9 ± 8.039.6 ± 10.1
SecondaryInterferon (INF)-Gamma

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · cells per 10^5 T cells
Interferon (INF)-Gamma
cells per 10^5 T cellsFluMistPlacebo
Interferon (INF)-Gamma17.0 ± 27.216.5 ± 25.9
SecondaryINF-Gamma

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · cells per 10^5 T cells
INF-Gamma
cells per 10^5 T cellsFluMistPlacebo
INF-Gamma28.6 ± 43.77.5 ± 7.6
SecondaryINF-Gamma

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · cells per 10^5 T cells
INF-Gamma
cells per 10^5 T cellsFluMistPlacebo
INF-Gamma28.0 ± 38.716.6 ± 27.0
SecondaryInterleukin (IL)-4

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · cells per 10^5 T cells
Interleukin (IL)-4
cells per 10^5 T cellsFluMistPlacebo
Interleukin (IL)-42.6 ± 4.35.5 ± 8.4
SecondaryIL-4

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · cells per 10^5 T cells
IL-4
cells per 10^5 T cellsFluMistPlacebo
IL-41.9 ± 2.72.6 ± 3.5
SecondaryIL-4

Mean and standard deviation spots-forming cells per 10\^5 T cells is reported.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · cells per 10^5 T cells
IL-4
cells per 10^5 T cellsFluMistPlacebo
IL-42.9 ± 3.94.7 ± 6.1
SecondaryHuman Leukocyte Antigen (HLA) Matched Tetramers CD8+

The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · Percentage of lymphocytes
Human Leukocyte Antigen (HLA) Matched Tetramers CD8+
Percentage of lymphocytesFluMistPlacebo
Human Leukocyte Antigen (HLA) Matched Tetramers CD8+11.045 ± 6.45212.778 ± 6.579
SecondaryHLA Matched Tetramers CD8+

The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · Percentage of lymphocytes
HLA Matched Tetramers CD8+
Percentage of lymphocytesFluMistPlacebo
HLA Matched Tetramers CD8+8.048 ± 6.7018.632 ± 4.126
SecondaryHLA Matched Tetramers CD8+

The antigen-specific response of the T cell populations was measured using HLA-matched tetramers specific for human CD8 cell populations.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · Percentage of lymphocytes
HLA Matched Tetramers CD8+
Percentage of lymphocytesFluMistPlacebo
HLA Matched Tetramers CD8+7.997 ± 3.14312.922 ± 8.607
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H1N1 Hemagglutination Inhibition (HAI) Titers From Baseline to Day 35-4210
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza A/H3N2 HAI Titers From Baseline to Day 35-4220
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal HAI titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Serum Influenza B HAI Titers From Baseline to Day 35-4210
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H1N1 Microneutralization Titers From Baseline to Day 35-4220
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Influenza A/H3N2 Microneutralization Titers From Baseline to Day 35-4220
SecondaryNumber of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42

Participants with a geometric mean fold-rise in influenza-specific nasal microneutralization titers \>= 4 from baseline are reported.

Time frame:
Baseline (pre-dosing on Day 0) and 35-42 days after study vaccination
Reported as:
Number · participants
Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-42
participantsFluMistPlacebo
Number of Participants Who Experienced a >= 4-fold Rise in Influenza B Microneutralization Titers From Baseline to Day 35-4210
SecondaryInfluenza A/H1N1 Immunoglobulin A (IgA)

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H1N1 Immunoglobulin A (IgA)
titerFluMistPlacebo
Influenza A/H1N1 Immunoglobulin A (IgA)0.8 ± 0.80.5 ± 0.0
SecondaryInfluenza A/H1N1 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
3-5 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgA
titerFluMistPlacebo
Influenza A/H1N1 IgA0.8 ± 0.70.5 ± 0.0
SecondaryInfluenza A/H1N1 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgA
titerFluMistPlacebo
Influenza A/H1N1 IgA1.1 ± 1.10.5 ± 0.0
SecondaryInfluenza A/H1N1 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
14-28 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgA
titerFluMistPlacebo
Influenza A/H1N1 IgA0.9 ± 0.91.1 ± 1.3
SecondaryInfluenza A/H1N1 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgA
titerFluMistPlacebo
Influenza A/H1N1 IgA1.3 ± 1.30.5 ± 0.0
SecondaryInfluenza A/H3N2 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H3N2 IgA
titerFluMistPlacebo
Influenza A/H3N2 IgA1.0 ± 0.80.7 ± 0.5
SecondaryInfluenza A/H3N2 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
3-5 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgA
titerFluMistPlacebo
Influenza A/H3N2 IgA0.7 ± 0.50.5 ± 0.0
SecondaryInfluenza A/H3N2 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgA
titerFluMistPlacebo
Influenza A/H3N2 IgA1.2 ± 0.80.7 ± 0.5
SecondaryInfluenza A/H3N2 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
14-28 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgA
titerFluMistPlacebo
Influenza A/H3N2 IgA0.7 ± 0.51.1 ± 0.9
SecondaryInfluenza A/H3N2 IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgA
titerFluMistPlacebo
Influenza A/H3N2 IgA1.7 ± 1.00.5 ± 0.0
SecondaryInfluenza B IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza B IgA
titerFluMistPlacebo
Influenza B IgA0.5 ± 0.00.5 ± 0.0
SecondaryInfluenza B IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
3-5 days after study vaccination
Reported as:
Mean · titer
Influenza B IgA
titerFluMistPlacebo
Influenza B IgA0.5 ± 0.00.5 ± 0.0
SecondaryInfluenza B IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · titer
Influenza B IgA
titerFluMistPlacebo
Influenza B IgA0.5 ± 0.00.5 ± 0.0
SecondaryInfluenza B IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
14-28 days after study vaccination
Reported as:
Mean · titer
Influenza B IgA
titerFluMistPlacebo
Influenza B IgA0.5 ± 0.00.5 ± 0.0
SecondaryInfluenza B IgA

Mean of influenza-specific IgA from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza B IgA
titerFluMistPlacebo
Influenza B IgA0.7 ± 0.50.5 ± 0.0
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD56

Mean and standard deviation results of CD56 lymphocyte subsets is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · percent of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
percent of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD567.6 ± 5.55.2 ± 3.2
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - CD56

Mean and standard deviation results of CD56 lymphocyte subsets is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · percent of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - CD56
percent of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - CD566.6 ± 5.64.6 ± 3.4
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells

Mean and standard deviation results of white blood cells subsets is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · cells per 10^3/UL
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
cells per 10^3/ULFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells3.91 ± 1.564.19 ± 1.49
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells

Mean and standard deviation results of white blood cells subsets is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · cells per 10^3/UL
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells
cells per 10^3/ULFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - White Blood Cells4.05 ± 1.333.24 ± 1.10
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes

Mean and standard deviation results of lymphocytes subsets is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · Percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes27.56 ± 9.2517.62 ± 7.56
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes

Mean and standard deviation results of lymphocytes subsets is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · Percentage of lymphocytes
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes
Percentage of lymphocytesFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Lymphocytes23.13 ± 8.2322.58 ± 11.89
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes

Mean and standard deviation results of absolute lymphocytes subsets is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · Cells per 10^3/UL
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Cells per 10^3/ULFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes1.03 ± 0.500.77 ± 0.51
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes

Mean and standard deviation results of absolute lymphocytes subsets is reported.

Time frame:
7-10 days after study vaccination
Reported as:
Mean · Cells per 10^3/UL
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes
Cells per 10^3/ULFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Lymphocytes0.98 ± 0.570.77 ± 0.58
SecondaryT- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils

Mean and standard deviation results of absolute neutrophils subsets is reported.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · Cells per 10^3/UL
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils
Cells per 10^3/ULFluMistPlacebo
T- and B-lymphocyte Subsets by Flow Cytometry - Absolute Neutrophils2728.6 ± 1162.93300.0 ± 1534.6
SecondaryInfluenza A/H1N1 Immunoglobulin G (IgG)

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H1N1 Immunoglobulin G (IgG)
titerFluMistPlacebo
Influenza A/H1N1 Immunoglobulin G (IgG)672.4 ± 492.8954.7 ± 1245.3
SecondaryInfluenza A/H1N1 IgG

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgG
titerFluMistPlacebo
Influenza A/H1N1 IgG844.0 ± 645.7924.3 ± 1207.2
SecondaryInfluenza A/H3N2 IgG

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H3N2 IgG
titerFluMistPlacebo
Influenza A/H3N2 IgG1842.4 ± 1989.1799.1 ± 426.2
SecondaryInfluenza A/H3N2 IgG

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgG
titerFluMistPlacebo
Influenza A/H3N2 IgG1671.9 ± 1646.6742.9 ± 432.2
SecondaryInfluenza B IgG

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza B IgG
titerFluMistPlacebo
Influenza B IgG638.6 ± 334.5599.1 ± 344.2
SecondaryInfluenza B IgG

Mean of influenza-specific IgG from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza B IgG
titerFluMistPlacebo
Influenza B IgG1020.3 ± 715.6620.2 ± 472.8
SecondaryInfluenza A/H1N1 Immunoglobulin M (IgM)

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H1N1 Immunoglobulin M (IgM)
titerFluMistPlacebo
Influenza A/H1N1 Immunoglobulin M (IgM)160.4 ± 105.4150.1 ± 107.0
SecondaryInfluenza A/H1N1 IgM

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H1N1 IgM
titerFluMistPlacebo
Influenza A/H1N1 IgM134.8 ± 100.7171.3 ± 106.7
SecondaryInfluenza A/H3N2 IgM

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza A/H3N2 IgM
titerFluMistPlacebo
Influenza A/H3N2 IgM134.7 ± 100.4153.1 ± 109.4
SecondaryInfluenza A/H3N2 IgM

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza A/H3N2 IgM
titerFluMistPlacebo
Influenza A/H3N2 IgM136.9 ± 103.1189.9 ± 98.5
SecondaryInfluenza B IgM

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
pre-dosing (Day 0)
Reported as:
Mean · titer
Influenza B IgM
titerFluMistPlacebo
Influenza B IgM72.2 ± 66.769.3 ± 61.0
SecondaryInfluenza B IgM

Mean of influenza-specific IgM from nasal swab is reported. Titers of \< 1 were assigned the value of 0.5.

Time frame:
35-42 days after study vaccination
Reported as:
Mean · titer
Influenza B IgM
titerFluMistPlacebo
Influenza B IgM68.4 ± 55.382.0 ± 69.7

Adverse events

Collected over Adverse events were collected from the time of investigational product administration through Day 42. Serious adverse events were collected from the time of study drug administration through Day 180.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/10 (30%)9/10 (90%)
FluMist—1/10 (10%)5/10 (50%)
Most frequent serious events
Most frequent serious events
EventPlaceboFluMist
Febrile neutropeniaBlood and lymphatic system disorders2/100/10
BacteraemiaInfections and infestations1/100/10
Herpes zosterInfections and infestations1/100/10
PneumoniaInfections and infestations1/100/10
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/101/10
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboFluMist
RashSkin and subcutaneous tissue disorders2/100/10
Febrile neutropeniaBlood and lymphatic system disorders1/100/10
ConjunctivitisEye disorders1/100/10
Abdominal pain upperGastrointestinal disorders1/100/10
ConstipationGastrointestinal disorders0/101/10
DiarrhoeaGastrointestinal disorders1/100/10
DyspepsiaGastrointestinal disorders1/100/10
NauseaGastrointestinal disorders1/100/10
Oral painGastrointestinal disorders1/100/10
Fungal skin infectionInfections and infestations1/100/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFluMistTotal
Mean12.2 ± 3.812.2 ± 3.912.2 ± 3.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFluMistTotal
Female4711
Male639
08

Study locations

5 sites
  • University of Rochester School of Medicine & Dentistry
    Rochester, New York 14642, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • St. Jude's Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Children's Hospital Regional Medical Center
    Seattle, Washington 98105, United States
09

References and documents

Publications

  • Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine. 2011 May 31;29(24):4110-5. doi: 10.1016/j.vaccine.2011.03.097. Epub 2011 Apr 13. PubMed 21496468 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2005 to primary completion in Mar 2008, 31 months.

Results were first posted in Sep 2012, 4 years 6 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 31 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2005
First posted
May 30, 2005
StartActual
Aug 1, 2005
Primary completionActual
Mar 1, 2008
CompletionActual
May 1, 2008
Results first posted
Sep 3, 2012
Last update
Aug 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00112112
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
May 30, 2005
Start date
Aug 1, 2005
Primary completion
Mar 1, 2008
Completion
May 1, 2008
Results posted
Sep 3, 2012
Last update
Aug 14, 2017

Study contacts

Raburn Mallory, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion